阿魏酸哌嗪在腹膜透析患者残余肾功能中的应用  

Application of popeazime Feyulate on FFR in CAPD patients

作　　者：张必嘏[1] 杜梅仙[1] 马晓燕[1] 舒方[1] 

机构地区：[1]上海市吴淞中心医院(上海市第一人民医院宝山分院)肾内科,上海200000

出　　处：《国际泌尿系统杂志》2009年第4期447-449,共3页International Journal of Urology and Nephrology

摘　　要：目的探索持续性腹膜透析（CAPD）的尿毒症患者使用阿魏酸哌嗪对残余肾功能（RRF）的影响。方法43例CAPD治疗的尿毒症患者随机分为治疗组与对照组，治疗组22例，对照21例；治疗组在对照组基础上加用中成药阿魏酸哌嗪，每次150mg，每天3次，疗程12个月；观察治疗前、后的血压（BP）、体重（BW）、血色素（Hb）、血尿素氮（BUN）、肌酐（Scr）、血白蛋白（Alb）等指标；分别检测二组治疗6、12、18个月的RRF及尿量。结果与对照组相比，治疗后的治疗组RRF下降速度减慢（P〈0．05），尿量减少明显减缓（P〈0．01），BP控制对照组满意（P〈0．05），Hb、BW、Alb好于对照组（P〈0．05～0．01）。结论阿魏酸哌嗪对CAPD尿毒症患者的RRF有保护作用，延缓尿量的减少，改善患者营养，提高CAPD患者的生活质量。Objectives To investigate the effect Pipeazime Feyulate on residual renal function （FFR）in continuous ambulatory peritoneal dialysis（CAPD） patients. Methods Fourty - three patients of uremia were randomly divided into two groups. 22 patients in the treated group and 21patients in the control group. All patients were treated by continuous ambulatory peritoneal dialysis （CAPD）. The patients of the treated group combined with Pipperazine ferulate 150mg 3times per day. The therapeutic course were 18months. The change in general condition blood pressure （ BP ）, body weight （ BW）, hemoglobin （ Hb）, blood ures nitrogen （BUN）, serum creatinine （ Scr ）, albumin（Alb） before and after treatment were observed. RRF and amount of urine measured before and after 6,12,18months treatment respectively. Results In the treated groyp, after treatment, the decline of RRF and amount of urine were significantly slower than those in the control group（ p 〈 0. 05 ）, also the levels of Bp in former were markedly better than later group（ p 〈 0. 05 ）, significant improvement were revealed in aspects of Hb, BW, Alb in the treated group（ p 〈0. 05 -0. 01 ）. Conclusions Piperazine Ferulate was effective in slowing domn the decrease of RRF and amount of urine,improving nutritional condition and quality of life in patients of uremia treated by CAPD.

关 键 词：持续性腹膜透析 阿魏酸哌嗪 残余肾功能 透析患者 CAPD治疗 尿毒症患者 尿量减少 CAPD患者 

分 类 号：R692.5[医药卫生—泌尿科学]